Airborne microorganisms pose a persistent challenge in healthcare facilities, laboratories and indoor environments. Conventional air filtration primarily focuses on removing particulate matter, while institutions also need solutions to address microbial contamination and monitor changes in indoor microbial conditions.
Product
Biomoneta's proprietary ZeBox technology uses an electric field to capture airborne microorganisms on an antimicrobial surface, where they are inactivated. Its portfolio includes Avata Rx for healthcare environments, Avata Air for homes and qAMI, a platform that estimates microbial levels and tracks environmental microbial trends.
Proof
In November 2025, Avata Rx received US FDA 510(k) clearance as a Class II medical recirculating air cleaner under K251872. In September 2026, Avata Air entered the consumer market through Panasonic's MirAIe Lifestyle platform. The company has also deployed its technology in healthcare and laboratory environments.
People
Co-founded by Arindam Ghatak, Dr. Janani Venkatraman and Dr. Santanu Datta, Biomoneta's leadership combines expertise in infectious-disease research, biotechnology and commercialisation. Its technical capabilities are further supported by Prof. Sujit Kumar Biswas, who brings extensive experience in power electronics and engineering.
Purse
In June 2020, Biomoneta announced seed funding led by Japan-based Beyond Next Ventures, through the C-CAMP–BNV Innovation Hub, alongside ArthaVida Ventures and angel investor Dr. Aniruddha Malpani. The company has also received institutional support from DBT-BIRAC, C-CAMP, the Government of Karnataka and the UK-supported GAMRIF programme. It is currently raising US$3 million to support its next phase of growth.
Plan
Biomoneta plans to expand its healthcare and consumer markets, strengthen distribution partnerships and scale manufacturing and customer support. It is also exploring international expansion and technology integration and licensing opportunities with equipment manufacturers, while developing qAMI's environmental surveillance capabilities.
Why it matters
Indoor air quality is an important dimension of infection prevention, particularly in hospitals and laboratories where microbial contamination can have significant consequences. By bringing microbial air treatment and environmental surveillance into one portfolio, Biomoneta is working towards a more comprehensive approach to managing indoor microbial conditions.
|
Particulars |
Details |
|---|---|
|
Company |
Biomoneta Research Private Limited |
|
Inception |
2014 |
|
Headquarters |
India |
|
Industry |
Biotechnology, Air Treatment, Infection Prevention |
|
Co-founders |
Arindam Ghatak, Dr. Janani Venkatraman, Dr. Santanu Datta |
|
Key Technology |
ZeBox |
|
Key Products |
Avata Rx, Avata Air, qAMI |
|
Regulatory Milestone |
US FDA 510(k) clearance for Avata Rx, November 2025 |
|
Consumer Launch |
Avata Air through Panasonic MirAIe Lifestyle, September 2026 |
|
Seed Investors |
Beyond Next Ventures, ArthaVida Ventures, Dr. Aniruddha Malpani |
|
Funding Support |
DBT-BIRAC, C-CAMP, Government of Karnataka, GAMRIF |
|
Current Fundraising |
US$3 million |
|
Website |